619 related articles for article (PubMed ID: 30736842)
1. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
2. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
3. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
5. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
6. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
7. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
Litzow MR
Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
[TBL] [Abstract][Full Text] [Related]
8. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
[TBL] [Abstract][Full Text] [Related]
9. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Jamison T; Paul S; Cuglievan B; McCall D; Gibson A; Jain N; Haddad FG; Nasr LF; Marx KR; Rausch C; Savoy JM; Garris R; Ravandi F; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e168-e173. PubMed ID: 38212207
[TBL] [Abstract][Full Text] [Related]
10. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
[TBL] [Abstract][Full Text] [Related]
11. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
13. Antibody based therapy in relapsed acute lymphoblastic leukemia.
Jammal N; Chew S; Jabbour E; Kantarjian H
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
Wynne J; Wright D; Stock W
Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
[TBL] [Abstract][Full Text] [Related]
15. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
[TBL] [Abstract][Full Text] [Related]
16. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
17. Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease.
Curran E; O'Brien M
Semin Hematol; 2020 Jul; 57(3):157-163. PubMed ID: 33256906
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia.
Ohana Z; Serraes S; Elder C; Katusa N
J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
20. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
Advani A
Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]